Immuron, Ltd.
Immuron Ltd is a publicly listed Australian biopharmaceutical company specializing in developing and commercializing targeted polyclonal antibodies. It has a strong focus on transforming treatments for infectious diseases such as Campylobacteriosis, Clostridioides difficile infections, ETEC infections, Shigellosis, and travelers’ diarrhea. The company markets products like Travelan® and Protectyn® and is engaged in extensive research collaborations with military, government, and academic institutions to advance its therapeutic pipeline.
Industries
Nr. of Employees
small (1-50)
Immuron, Ltd.
Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Patents
Methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease
US-10144775-B2
View DetailsComposition and method for the treatment and prevention of enteric bacterial infections
US-8637025-B2
View Details
Methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease
US-10144775-B2
View DetailsComposition and method for the treatment and prevention of enteric bacterial infections
US-8637025-B2
View DetailsProducts
Travelan
Orally administered colostrum-derived polyclonal antibody product marketed to reduce the risk of travellers' diarrhea and to support gastrointestinal health; supplied as oral caplets and powders.
Protectyn
Orally administered colostrum-derived product enriched for antibodies binding bacterial lipopolysaccharide (LPS), intended to support digestive and liver health by binding LPS and associated bacteria in the gut.
IMM-529 (C. difficile therapeutic candidate)
Oral polyclonal antibody investigational drug candidate developed to target Clostridioides difficile toxin B, spores and vegetative cells; manufactured for clinical development and intended to treat or prevent C. difficile infection.
Travelan
Orally administered colostrum-derived polyclonal antibody product marketed to reduce the risk of travellers' diarrhea and to support gastrointestinal health; supplied as oral caplets and powders.
Protectyn
Orally administered colostrum-derived product enriched for antibodies binding bacterial lipopolysaccharide (LPS), intended to support digestive and liver health by binding LPS and associated bacteria in the gut.
IMM-529 (C. difficile therapeutic candidate)
Oral polyclonal antibody investigational drug candidate developed to target Clostridioides difficile toxin B, spores and vegetative cells; manufactured for clinical development and intended to treat or prevent C. difficile infection.
Expertise Areas
- Polyclonal antibody therapeutics for enteric pathogens
- Oral delivery of antibody biologics targeted to the gastrointestinal tract
- Preclinical animal challenge modelling
- Controlled human infection model (CHIM) clinical trials
Key Technologies
- Hyperimmune bovine colostrum production
- Polyclonal antibody generation and enrichment
- Oral biologic dosage form formulation and lyophilization
- cGMP manufacturing for biologic drug substance